PharmTech News

Articles

The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.

BioMed X Launches Drug Delivery Research Project with Janssen

Sanofi will offer access to its infrastructure and expertise to help BioNTech produce over 125 million doses of its COVID-19 vaccine in Europe.

Sanofi to Help Manufacture and Supply BioNTech’s COVID-19 Vaccine

The two facilities consist of 260 and 130 permanent staff members respectively and produce liquid-filled hard capsules and softgels for the pharmaceutical market as well as other markets.

NextPharma to Acquire Two of Lonza’s European Facilities 

Estonia, Hungary, and Iceland have signed up to take part in a pilot of Guardtime's VaccineGuard—a newly developed platform aimed at supporting the global COVID-19 vaccination program.

Estonia, Hungary, and Iceland Sign Up to Pilot VaccineGuard from Guardtime

A new report from the University of Strathclyde’s Fraser of Allander Institute has demonstrated the strength of the pharmaceutical sector in Scotland.

New Report Shows Strength of Scotland’s Pharma Industry

DHL Global Forwarding has expanded its life sciences and healthcare facility in Leipzig, Germany.

DHL Expands Life Sciences and Healthcare Facility in Germany

GlaxoSmithKline (GSK) and Novartis have announced the launch of a collaboration to support scientific research into genetic diversity in Africa and the potential impact in response to drugs.

GSK, Novartis Collaborate on Project Africa GRADIENT

The approval was based on positive results from a single-arm Phase II trial where the treatment demonstrated significant antitumor activities in patients with the disease.

AstraZeneca and Daiichi Sankyo’s Breast Cancer Treatment Approved for Use in Europe

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

The acquisition will give Sanofi full global rights to KY1005, Kymab’s fully human monoclonal antibody that binds to OX40-Ligand, giving it the potential to treat a variety of immune-mediated diseases and inflammatory disorders. 

PharmTech Europe News